Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Nurix brings in $25.1mm in Series B round

Executive Summary

Nurix Inc. (developing ubiquitin proteasome system (UPS) modulators for cancer and other diseases) raised $25.1mm through its Series B round from Third Rock Ventures and The Column Group. The investors also participated in Nurix’s $6.2mm seed financing in 2012.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies